CMA costs dispute goes to Supreme Court
The UK's Supreme Court has permitted Flynn Pharma and Pfizer to appeal against a ruling that required the drug companies to pay the costs of their successful appeal against a decision by the UK's Competition and Markets Authority.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.